When a janitorial supply can save a life
Posted February 02, 2018 12:14:19 A team of researchers at the University of Washington School of Medicine has identified a new antibiotic that could save the lives of many people with a serious illness and lead to more efficient use of medicine.
The team, led by the Washington State School of Pharmacy, is reporting their findings online in the journal PLOS ONE.
“We believe that we have found a novel class of antibiotics that we think is a lot better than the ones currently available,” said senior author Dr. Paul J. Schlegel.
“The novel antibiotics have great promise for managing a wide range of infectious diseases.”
The antibiotic class they describe is the genus Nepomucor, which is related to the genus of penicillium that includes penicillin, ampicillin and streptomycin.
The researchers identified three classes of antibiotic compounds that are used to treat a range of infections, including:the most common class, called the cephalosporins;the second class, known as the floxacin-type antibiotics; and a class of drugs known as neomycin-type.
“Neomycin is one of the most effective antibiotics and is used in the treatment of tonsillitis, urinary tract infections and a range, including pneumonia,” said Dr. Schlimel.
The authors also found that the class of cephagenics was a significant contributor to the overall mortality rate of people with severe infections.
“The most important benefit of this class of antibiotic is that it is not an antibiotic that can kill bacteria in the patient,” said study lead author Dr James W. Bouchard, M.D., Ph.
D. “Instead, it protects the body from bacterial infection and is a natural killer.”
“The antibiotic cephelin can kill many types of bacteria,” said lead researcher Dr. Broussard.
“But its use should not be overstated.”
“It’s very important to note that the mortality rate for patients with pneumonia and tonsillosis is much higher than for those with pneumonia,” he added.
The study is the first to evaluate the effects of neomycins on patients with serious infections in the general population.
The primary purpose of the study was to compare the effects on the mortality of patients with pneumococcal pneumonia and pneumococcus infection in the United States with the mortality rates for those without serious infections.
The research team examined mortality rates of people ages 65 and older with pneumonia at different times between the years of 2011 and 2018.
Mortality rates ranged from 0.3 percent to 4.3 per 100,000, depending on age.
The researchers then compared mortality rates between the two groups and between the groups with pneumococcosis.
The overall mortality rates were 4.7 percent for people with pneumoconiosis and 3.7 per 100.000 for those who did not have pneumonia.
The overall mortality ratios for people without pneumonia were 8.2 per 100 for people age 65 and above, 7.1 per 100 people 65 and under and 7.0 per 100 individuals aged 18-49.
“This study provides strong evidence that the use of cefixime, a neomycolinic antibiotic, can lower mortality rates in patients with severe pneumonia,” Schlime said.
“While we know that neomycillin is a very good antibiotic, the effectiveness of neomucin in the prevention of death is unknown.”
The researchers say that the study provides some additional insight into the effect of the antibiotic class of neomicins on the incidence of death in people with pneumonia.
“Our results indicate that cefirosporins have a significant impact on the overall survival rate of patients,” Schlege said, “and that they also have a protective effect against pneumoconia, a common form of pneumonia.”
The team says their study is not a clinical trial, but a observational study.
They say that more studies are needed to determine the impact of the new class of antimicrobials.###Follow The Washington Post Health team at:www.washpost.com/health/